In a strategic move to advance its weight loss drug development, Pfizer is set to launch a revamped, once-a-day version of its danuglipron pill into clinical trials later this year. The decision comes after the pharmaceutical giant discarded a twice-daily variant of the drug in late 2021 due to high dropout rates in midstage trials attributed to severe side effects like nausea and vomiting.
This new iteration of danuglipron is part of a new wave of next-generation weight-loss medications being developed by industry peers such as Eli Lilly and Novo Nordisk, which aim to provide patients with a more convenient alternative to traditional injections. With analysts predicting the weight-loss drug market - currently dominated by Novo Nordisk's Wegovy and Eli Lilly's Zepbound - to exceed $150 billion in annual sales by the early 2030s, Pfizer's focus on the reformulated Danuglipron signifies a significant strategic move.
Following the discontinuation of lotiglipron, another weight loss drug under development by Pfizer, due to safety concerns regarding liver enzyme elevations in patients, the company aims to make a comeback with the once-daily danuglipron. Early study results have shown promising outcomes, including no observed liver enzyme elevations in a cohort of over 1,400 healthy adult volunteers.
GLP-1s, originally intended for managing type 2 diabetes, work by mimicking the GLP-1 hormone to regulate blood sugar levels, slow digestion, and suppress appetite. Pfizer's pursuit of a more effective and safer weight loss drug is in line with the broader industry trend, with other pharmaceutical players like Amgen and Viking Therapeutics also delving into developing next-generation weight loss medications.
The recent decrease in sales of Pfizer's COVID-19 products has led to investor concerns about the company's growth prospects, putting pressure on CEO Albert Bourla to drive revenue through new pharmaceutical products. The announcement of Chief Scientific Officer Mikael Dolsten's departure after a lengthy stint with Pfizer signals a reorganization within the company's leadership, as it navigates the evolving landscape of pharmaceutical drug development.
Overall, Pfizer's move to push forward with a once-daily version of danuglipron underscores its commitment to innovation in the weight loss drug market, positioning itself for success in the competitive pharmaceutical landscape.